225AС-PSMA-617 therapy in metastatic castration-resistant prostate cancer

177Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic prostate cancer (mCRPC) with proven efficacy. 225Ac-PCMA-617 is an alpha emitter, making this drug potentially more powerful. Despite the active use of 225Ac-PSMA-617 worldwide, no randomized phase III studies have yet been conducted. The present prospective cohort study presents the experience of 225Ac-PSMA-617 use in the A.F. Tsyb MRRC. Material and Methods. The study included mCRPC patients with prostate-specific membrane antigen (PSMA) overexpression confirmed by PET-CT or SPECT-CT, who received the first course of therapy in 2023.